Biotech Values

[isolution]

Injection rate rationale

Dew, I perfectly agree, injection rate is a BIG near-term issue.

The PR from Genvec below supports perfectly the idea.

http://www.genvec.com/download/press/AdPEDF%20enrollment%20FINALOUT.pdf


Patients in that study showed evidence of a halt in disease progression lasting six to twelve months after a single intravitreous injection of AdPEDF.

and

New therapies to treat AMD have demonstrated benefit but these therapies must be injected every four to six weeks. GenVec believes its gene transfer approach may provide an effective and more convenient treatment for AMD.

I am not much in favor of adenoviral approach, but it's a way to solve frequent injection problem, just as Oxigene is trying to do.